
    
      The study will comprise:

        -  Screening period: up to 28 days prior to first dosing;

        -  Three treatment periods of maximum 3 days each: participants will be resident from the
           morning of the day before the first dosing with BGF MDI (Day -1) in Treatment Period 1,
           throughout all treatment and washout periods up to discharge on Day 2 of Treatment
           Period 3;

        -  Follow-up: within 3 to 7 days after the last administration of BGF MDI. There will be a
           washout period of 3 to 7 days between each dose.

      Each participant will receive 3 single-dose treatments of BGF MDI (1 dose Propellant 1
      [Treatment A]; 1 dose Propellant 2 [Treatment B] and 1 dose HFA [Treatment C]), following an
      overnight fast of at least 8 hours. Each participant will be involved in the study for up to
      53 days.
    
  